Literature DB >> 17579921

Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection.

Aileen Kenneson1, Michael J Cannon.   

Abstract

We reviewed studies that reported results of systematic cytomegalovirus (CMV) screening on fetuses and/or live-born infants. The overall birth prevalence of congenital CMV infection was 0.64%, but varied considerably among different study populations. About 11% of live-born infants with congenital CMV infection were symptomatic, but the inter-study differences in definitions of symptomatic cases limit the interpretation of these data. Non-white race, low socioeconomic status (SES), premature birth, and neonatal intensive care unit admittance were risk factors for congenital CMV infection. Birth prevalence increased with maternal CMV seroprevalence. Maternal seroprevalence accounted for 29% of the variance in birth prevalence between study populations. Maternal seroprevalence and birth prevalence were both higher in study populations that were ascertained at birth rather than in the prenatal period. Thus, timing of ascertainment should be considered when interpreting birth prevalence estimates. Birth prevalence was inversely correlated with mean maternal age, but this relationship was not significant when controlling for maternal seroprevalence. The rate of transmission to infants born to mothers who had a primary infection or a recurrent infection during pregnancy was 32% and 1.4%, respectively. Possible maternal primary infections (i.e. seropositive mother with CMV IgM) resulted in congenital infections about 20% of the time, but are likely to represent a mixture of primary and recurrent infections. In summary, CMV is a common congenital infection worldwide that can lead to permanent disabilities. There is an urgent need for interventions that can reduce the substantial burden of this often overlooked disease.

Entities:  

Mesh:

Year:  2007        PMID: 17579921     DOI: 10.1002/rmv.535

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  440 in total

Review 1.  Ethical and Public Health Implications of Targeted Screening for Congenital Cytomegalovirus.

Authors:  Ladawna L Gievers; Alison Volpe Holmes; Jaspreet Loyal; Ilse A Larson; Carlos R Oliveira; Erik H Waldman; Sheevaun Khaki
Journal:  Pediatrics       Date:  2020-07       Impact factor: 7.124

Review 2.  Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus.

Authors:  Sheila C Dollard; Mark R Schleiss; Scott D Grosse
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

3.  Cytomegalovirus survival on common environmental surfaces: opportunities for viral transmission.

Authors:  Jennifer D Stowell; Daniela Forlin-Passoni; Erica Din; Kay Radford; Denise Brown; Audrey White; Sheri L Bate; Sheila C Dollard; Stephanie R Bialek; Michael J Cannon; D Scott Schmid
Journal:  J Infect Dis       Date:  2011-11-23       Impact factor: 5.226

4.  Rapid genotyping of cytomegalovirus in dried blood spots by multiplex real-time PCR assays targeting the envelope glycoprotein gB and gH genes.

Authors:  Jutte J C de Vries; Els Wessels; Anna M H Korver; Annemiek A van der Eijk; Lisette G Rusman; Aloys C M Kroes; Ann C T M Vossen
Journal:  J Clin Microbiol       Date:  2011-11-23       Impact factor: 5.948

5.  Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities.

Authors:  Sara Ornaghi; Lawrence S Hsieh; Angélique Bordey; Patrizia Vergani; Michael J Paidas; Anthony N van den Pol
Journal:  J Neurosci       Date:  2017-06-19       Impact factor: 6.167

6.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

7.  Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009-2015.

Authors:  Jessica Leung; Sheila C Dollard; Scott D Grosse; Winnie Chung; ThuyQuynh Do; Manisha Patel; Tatiana M Lanzieri
Journal:  Clin Ther       Date:  2018-02-04       Impact factor: 3.393

8.  An unbiased proteomics approach to identify human cytomegalovirus RNA-associated proteins.

Authors:  Erik M Lenarcic; Benjamin J Ziehr; Nathaniel J Moorman
Journal:  Virology       Date:  2015-03-09       Impact factor: 3.616

Review 9.  Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in offspring of women with immunity prior to pregnancy.

Authors:  William Britt
Journal:  Med Microbiol Immunol       Date:  2015-03-13       Impact factor: 3.402

10.  Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer.

Authors:  Anna Kabanova; Jessica Marcandalli; Tongqing Zhou; Siro Bianchi; Ulrich Baxa; Yaroslav Tsybovsky; Daniele Lilleri; Chiara Silacci-Fregni; Mathilde Foglierini; Blanca Maria Fernandez-Rodriguez; Aliaksandr Druz; Baoshan Zhang; Roger Geiger; Massimiliano Pagani; Federica Sallusto; Peter D Kwong; Davide Corti; Antonio Lanzavecchia; Laurent Perez
Journal:  Nat Microbiol       Date:  2016-06-06       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.